Jules Bordet Institute

Pelareorep Plus Paclitaxel Shows Survival Benefit in HR+/HER2- Breast Cancer

8 months ago

• The combination of pelareorep and paclitaxel demonstrated a significant improvement in overall survival (OS) compared to paclitaxel alone in patients with HR+/HER2- metastatic breast cancer. • In the BRACELET-1 trial, the median OS was not reached in the pelareorep/paclitaxel arm, while it was 18.2 months in the paclitaxel monotherapy arm (HR, 0.48). • The 2-year survival rate was 64% in the pelareorep/paclitaxel group versus 33% in the paclitaxel monotherapy group, indicating a substantial survival advantage. • Progression-free survival (PFS) also improved with the combination therapy, showing a median PFS of 12.1 months compared to 6.4 months with paclitaxel alone (HR, 0.39).